An observational study in Idiopathic Pulmonary Fibrosis, sponsored by Aarhus University Hospital. Completed at 3 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-06.
Sponsored by Aarhus University Hospital · Observational
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with a high mortality. Health-related quality of life (HRQL) is impaired in patients with IPF. Little is known about the properties of recently developed HRQL questionnaires and about the longitudinal changes in HRQL, including factors with an impact on HRQL. Comorbidities have an impact on patients with IPF, but reports differ in incidence and prevalence. The impact of comorbidities on HRQL and disease progression has only been studied sparsely. Also, the association between biomarkers and disease progression need to be examined further.
680 studies on the registry are indexed under Pulmonary Fibrosis; 119 are open to participants now.
This study's enrollment of 150 is above the median of 130 across 229 observational studies indexed under Pulmonary Fibrosis.
Browse Pulmonary Fibrosis studies →Aarhus University Hospital is the lead sponsor of 289 studies on the registry; 79 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Incident and prevalent patients with IPF in Denmark.
Exclusion Criteria:
Health-related quality of life
Change in St. George's Respiratory Questionnaire
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Health-related quality of life
Change in St. George's Respiratory Questionnaire, IPF-specific
Time frame: Baseline, 2 weeks, 6 months, 12 months, 24 months, 36 months
Health-related quality of life
Changes in King's Brief Interstitial Lung Disease questionnaire
Time frame: Baseline, 2 weeks, 6 months, 12 months, 24 months, 36 months
Number and type of comorbidities
Prevalence of comorbidities at baseline
Time frame: Baseline
Number and type of comorbidities
Incidence of new comorbidities after 6 months, 12 months, 24 months and 36 months
Time frame: Change/incidence at 6 months, 12 months, 24 months and 36 months
Lung function tests
Change in forced vital capacity
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Lung function tests
Change in diffusion capacity for carbon monoxide
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
6-minute walk test
Change in 6-minute walk test
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Progression in serum/plasma biomarker levels
Increase or decrease in serum/plasma biomarker levels
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Health-related quality of life
Change in Short Form 36
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Health-related quality of life
Changes in University of California San Diego Shortness Of Breath Questionnaire
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Disease progression
Change in interstitial changes on high resolution CT-scan (HRCT)
Time frame: Baseline, 12 months, 24 months, 36 months
Disease progression
Changes in number of acute exacerbations
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Disease progression
Changes in use of supplementary oxygen
Time frame: Baseline, 6 months, 12 months, 24 months, 36 months
Plan to share: Undecided
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aarhus University Hospital